Breast and lung imaging software developer Volpara Health has further expanded its presence in the U.S. lung screening market via a new strategic partnership with Seattle-based artificial intelligence (AI) company RevealDx, formerly known as Mindshare Medical.
Volpara will be integrating RevealDx's RevealAI-Lung radiomics and AI decision-support software into Volpara Lung, its integrated reporting, tracking, and risk assessment platform for lung cancer screening. Volpara Lung currently features structured reporting, customizable reminders, and more than 40 statistical reports to monitor and track patients, according to the vendor. In addition, it supports submissions to the American College of Radiology Lung Cancer Screening Registry for reimbursement.
Earlier in September, Volpara also formed a partnership with AI software developer Riverain Technologies to access that firm's ClearRead lung nodule detection software.
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
